Radient Pharmaceuticals Corporation fka RXPC

[mlkrborn]

up 015 on commercialization news: above 52 weeks low level of 020.
9:35AM Radient Pharm shares open sharply higher after co announces target market details for the domestic and international commercialization of its Onko-Sure in vitro diagnostic cancer test (RPC) 0.51 +0.11 : Shares of RPC are trading higher by ~30% following the open of pit trade this morning after the co announced target market details for the domestic and international commercialization of its Onko-Sure in vitro diagnostic cancer test. Onko-Sure Commercialization Plan As RPC executes its domestic and international Onko-Sure sales plan, the co is focusing on 4 key target markets, that include: 1) US FDA approved use and sales of Onko-Sure as a CRC Monitoring Test in the U.S. & eventually Canada; 2) US FDA approved use and sales of Onko-Sure as a CRC Monitoring Test in various international markets; 3) use and sales of Onko-Sure as a general cancer screening test; and, 4) Health Canada approved use and sales of Onko-Sure as a lung cancer screening and